Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Topotecan in Pediatric Refractory Meningeal Malignancies
NCT00005811Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2000
- Primary completion
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of topotecan in leptomeningeal disease (LMD), sponsored by National Cancer Institute. Primary endpoints: Objective Response Rate up to 54 months, Event-Free Survival up to 54 months and 2 more. Started Apr 2000; status: completed.
02
Drugs
topotecan
03
Conditions
leptomeningeal disease (LMD)
Beyond the preview
Go deeper on NCT00005811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005811.